Exchange: NASDAQ·Updated 09:49 PM EDT
BMEA logo

BMEA Biomea Fusion Inc

$1.75
$0.04
(2.34%)
Overnight
Prev Close $1.71
Reported EarningsAug 5
Mkt Cap$125.4M
Vol3.22M

About BMEA

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
87

Extremely Bullish Sentiment

How do you feel about BMEA?

Advertisement|Remove ads.